• {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}
      • logo ubrevly
      Product Monograph
      PATIENT INFORMATION
      Important Safety Information

      UBRELVY is indicated for the acute treatment of migraine, with or without aura, in adults.

      FOR PATIENTS LIKE…

      patient 1
      patient 1
      patient 1

      Diagnosed with migraine 2 years ago.

      Symptoms: Increased headache intensity and duration over the last year.

      Considerations: Marnie has been self-managing her headaches with OTC medications.

      patient 2
      patient 2
      patient 2

      Diagnosed with migraines 6 years ago.

      Symptoms: Moderate to severe throbbing pain about once a week.

      Considerations: Jennifer has expressed tolerability concerns relating to medication.

      DOWNLOAD UBRELVY Patient Brochure (English)
      DOWNLOAD UBRELVY Patient Brochure (French)

      separator

      FOR PATIENTS LIKE…

      patient 1
      patient 1
      patient 1

      Diagnosed with migraine 2 years ago.

      Symptoms: Increased headache intensity and duration over the last year.

      Considerations: Marnie has been self-managing her headaches with OTC medications.

      patient 2
      patient 2
      patient 2

      Diagnosed with migraines 6 years ago.

      Symptoms: Moderate to severe throbbing pain about once a week.

      Considerations: Jennifer has expressed tolerability concerns relating to medication.

      DOWNLOAD UBRELVY Patient Brochure (English)
      DOWNLOAD UBRELVY Patient Brochure (French)

      separator

      FOR PATIENTS LIKE…

      patient 1
      patient 1
      patient 1

      Diagnosed with migraine 2 years ago.

      Symptoms: Increased headache intensity and duration over the last year.

      Considerations: Marnie has been self-managing her headaches with OTC medications.

      patient 2
      patient 2
      patient 2

      Diagnosed with migraines 6 years ago.

      Symptoms: Moderate to severe throbbing pain about once a week.

      Considerations: Jennifer has expressed tolerability concerns relating to medication.

      DOWNLOAD UBRELVY Patient Brochure (English)
      DOWNLOAD UBRELVY Patient Brochure (French)

      separator

      SAFETY INFORMATION

      Click here for additional safety information and for a link to the Product Monograph discussing:

      ●Contraindications with concomitant use of strong CYP3A4 inhibitors.

      ●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breastfeeding women and dose selection in geriatric patients.

      ●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

       

      FOR MORE INFORMATION

      For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011. 

      SAFETY INFORMATION

      Click here for additional safety information and for a link to the Product Monograph discussing:

      ●Contraindications with concomitant use of strong CYP3A4 inhibitors.

      ●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breastfeeding women and dose selection in geriatric patients.

      ●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

       

      FOR MORE INFORMATION

      For any questions related to UBRELVY, you can contact AbbVie Medical Information at 1-844-241-5011. 

      SAFETY INFORMATION

      Click here for additional safety information and for a link to the Product Monograph discussing:

      ●Contraindications with concomitant use of strong CYP3A4 inhibitors.

      ●Relevant warnings and precautions regarding driving and operating machinery, hypersensitivity reactions, may reduce effectiveness of oral contraceptives, use in pregnant or breastfeeding women and dose selection in geriatric patients.

      ●Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

       

      FOR MORE INFORMATION

      For any questions related to UBRELVY, you can contact AbbVie Medical Information at
      1-844-241-5011. 

      *Fictitious case. May not be representative of general population.

      *Fictitious case. May not be representative of general population.

      UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation. 

      © 2026 AbbVie. All rights reserved. 

      CA-UBR-260029A / JN26  

      UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation. 

      © 2026 AbbVie. All rights reserved. 

      CA-UBR-260029A / JN26  

      This website is intended for Canadian Healthcare Professionals

      Copyright © 2026 AbbVie Corporation. All rights reserved.

      Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.